131 related articles for article (PubMed ID: 35911441)
21. Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer.
Zito CI; Riches D; Kolmakova J; Simons J; Egholm M; Stern DF
Genes Chromosomes Cancer; 2008 Jul; 47(7):633-8. PubMed ID: 18418848
[TBL] [Abstract][Full Text] [Related]
22. Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.
Pfarr N; Penzel R; Endris V; Lier C; Flechtenmacher C; Volckmar AL; Kirchner M; Budczies J; Leichsenring J; Herpel E; Noske A; Weichert W; Schneeweiss A; Schirmacher P; Sinn HP; Stenzinger A
Genes Chromosomes Cancer; 2017 Apr; 56(4):255-265. PubMed ID: 27792260
[TBL] [Abstract][Full Text] [Related]
23. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.
Millis SZ; Ikeda S; Reddy S; Gatalica Z; Kurzrock R
JAMA Oncol; 2016 Dec; 2(12):1565-1573. PubMed ID: 27388585
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in
Uchida S; Kojima T; Sugino T
Pathol Oncol Res; 2021; 27():633243. PubMed ID: 34257600
[TBL] [Abstract][Full Text] [Related]
25. EGFR and erbB2 mutation status in Japanese lung cancer patients.
Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y
Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726
[TBL] [Abstract][Full Text] [Related]
26.
Uchida S; Sugino T
Curr Issues Mol Biol; 2023 Sep; 45(9):7404-7416. PubMed ID: 37754252
[TBL] [Abstract][Full Text] [Related]
27. Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2
Vasmatzis G; Wang X; Smadbeck JB; Murphy SJ; Geiersbach KB; Johnson SH; Gaitatzes AG; Asmann YW; Kosari F; Borad MJ; Serie DJ; McLaughlin SA; Kachergus JM; Necela BM; Thompson EA
BMC Cancer; 2018 Jul; 18(1):738. PubMed ID: 30005627
[TBL] [Abstract][Full Text] [Related]
28. Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.
Ross DS; Zehir A; Cheng DT; Benayed R; Nafa K; Hechtman JF; Janjigian YY; Weigelt B; Razavi P; Hyman DM; Baselga J; Berger MF; Ladanyi M; Arcila ME
J Mol Diagn; 2017 Mar; 19(2):244-254. PubMed ID: 28027945
[TBL] [Abstract][Full Text] [Related]
29. DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway.
Adam L; San Lucas FA; Fowler R; Yu Y; Wu W; Liu Y; Wang H; Menter D; Tetzlaff MT; Ensor J; Manyam G; Arold ST; Huff C; Kopetz S; Scheet P; Overman MJ
Clin Cancer Res; 2019 Jan; 25(2):641-651. PubMed ID: 30352910
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
[TBL] [Abstract][Full Text] [Related]
31. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
[TBL] [Abstract][Full Text] [Related]
32. Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysis.
Zhou C; Feng X; Yuan F; Ji J; Shi M; Yu Y; Zhu Z; Zhang J
Cancer Manag Res; 2018; 10():3945-3954. PubMed ID: 30310315
[TBL] [Abstract][Full Text] [Related]
33. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
[TBL] [Abstract][Full Text] [Related]
34. Activating human epidermal growth factor receptor 2 (HER2) gene mutation in bone metastases from breast cancer.
Christgen M; Bartels S; Luft A; Persing S; Henkel D; Lehmann U; Kreipe H
Virchows Arch; 2018 Nov; 473(5):577-582. PubMed ID: 30094493
[TBL] [Abstract][Full Text] [Related]
35. High-Throughput Functional Evaluation of Variants of Unknown Significance in
Nagano M; Kohsaka S; Ueno T; Kojima S; Saka K; Iwase H; Kawazu M; Mano H
Clin Cancer Res; 2018 Oct; 24(20):5112-5122. PubMed ID: 29967253
[No Abstract] [Full Text] [Related]
36. High Frequency of Juxtamembrane Domain
Park S; Ahn S; Kim DG; Kim H; Kang SY; Kim KM
Cancer Genomics Proteomics; 2022; 19(1):105-112. PubMed ID: 34949663
[TBL] [Abstract][Full Text] [Related]
37. Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.
Claerhout S; Lehnert S; Vander Borght S; Spans L; Dooms C; Wauters E; Vansteenkiste J; Weynand B; Deraedt K; Bourgain C; Vanden Bempt I
Lung Cancer; 2022 Apr; 166():242-249. PubMed ID: 35378489
[TBL] [Abstract][Full Text] [Related]
38. Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.
Christgen M; van Luttikhuizen JL; Raap M; Braubach P; Schmidt L; Jonigk D; Feuerhake F; Lehmann U; Schlegelberger B; Kreipe HH; Steinemann D
Oncotarget; 2016 Dec; 7(50):82733-82740. PubMed ID: 27716627
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
[TBL] [Abstract][Full Text] [Related]
40. Molecular and clinicopathological characteristics of
Guan Y; Wang Y; Li H; Meng J; You X; Zhu X; Zhang Q; Sun T; Qi C; An G; Fan Y; Xu B
Front Oncol; 2022; 12():986674. PubMed ID: 36276102
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
